Cellectis (NASDAQ:CLLS) Upgraded to Buy at StockNews.com

Cellectis (NASDAQ:CLLS) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday.

Cellectis Trading Up 5.0 %

CLLS stock opened at $1.22 on Wednesday. Cellectis has a 12-month low of $1.10 and a 12-month high of $3.38. The stock has a market cap of $67.70 million, a price-to-earnings ratio of -0.94 and a beta of 3.22. The business’s 50-day moving average is $1.37 and its 200 day moving average is $1.68. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $33.22 million during the quarter, compared to analyst estimates of $5.90 million. On average, sell-side analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of institutional investors and hedge funds have recently modified their holdings of CLLS. B Group Inc. purchased a new position in Cellectis during the fourth quarter worth about $5,547,000. Millennium Management LLC acquired a new stake in Cellectis during the 4th quarter valued at approximately $962,000. Finally, Wells Fargo & Company MN lifted its position in shares of Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 12,500 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.